DFTX
Definium Therapeutics, Inc. Common Shares
Nasdaq · usd
Definium Therapeutics, Inc. Common Shares (DFTX) trades at $36.10 (+1.21%) as of 2:22:42 PM EDT on Oct 26, 2026, -0.11% over the past month. Market cap is $4.79B, with 4.9 days to cover in short interest.
Stock performance
How Definium Therapeutics, Inc. Common Shares (DFTX) stock has performed from one day to one year, with its 52-week range.
- 1D
- +1.29%
- 1W
- +9.58%
- 1M
- -0.11%
- YTD
- +134.92%
- 1Y
- +134.92%
- 52-wk range
- $14.62 – $49.70
Key statistics
Today's trading snapshot for DFTX: day range, open, previous close, volume and market cap.
- Day range
- $34.74 – $36.35
- Open
- $35.60
- Prev close
- $35.67
- Volume
- 595.4K
- Market cap
- $4.79B
- Shares out
- 134.37M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Definium Therapeutics, Inc. Common Shares: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 5.22
- P/FCF
- —
- ROE
- -38.5%
- ROA
- -31.8%
- Debt/Equity
- 0.04
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Definium Therapeutics, Inc. Common Shares has disclosed to the SEC on Form 8-K.
- Investor presentationSep 14, 2026
On September 14, 2026, the Company posted a presentation discussing the Panorama topline data (the "Presentation") to its website.
- Regulatory decisionSep 8, 2026
On September 8, 2026, Definium Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") announcing that the U.S. Food and Drug Administration has granted breakthrough designation to the Company's DT120 ODT program for the treatment of major depressive disorder.
- Clinical trial resultsAug 12, 2026
On August 12, 2026, Definium Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") announcing positive topline data from the Company's Phase 3 Voyage study of DT120 ODT for the treatment of generalized anxiety disorder.
- Public offeringJun 24, 2026
On June 23, 2026, Definium Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, and BofA Securities, Inc., as representatives of the several underwriters named therein, in connection with an underwritten public offering of 20,588,236 common shares of the Company, without par value. The public offering price for the Shares is $34.00 per share.
- Clinical trial resultsJun 22, 2026
On June 22, 2026, Definium Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") announcing positive topline data from the Company's Phase 3 Emerge study of DT120 ODT for the treatment of major depressive disorder.
DFTX short interest
How heavily DFTX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.9
- Short interest
- 11.34M
- Avg volume
- 2.32M
As of · reported to FINRA twice monthly.
DFTX news
The latest news and headlines about Definium Therapeutics, Inc. Common Shares (DFTX).
- Definium Reports Second Phase III Success in Anxiety Disorder ProgrampositiveZacks Investment Research· Sep 15, 2026
- These 3 Psychedelic Stocks Activated After Trump’s Executive OrderpositiveInvesting.com· Apr 27, 2026
- Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to SoarpositiveThe Motley Fool· Apr 20, 2026
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentspositiveBenzinga· Feb 27, 2026
Frequently asked questions
What is the Definium Therapeutics, Inc. Common Shares (DFTX) stock price today?
Definium Therapeutics, Inc. Common Shares (DFTX) is trading at $36.10 (+1.21% on the day) as of 2:22:42 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Definium Therapeutics, Inc. Common Shares?
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction.
What is the short interest in DFTX?
As of Sep 30, 2026, DFTX has 11.34M shares short and 4.9 days to cover.
What exchange is DFTX listed on?
Definium Therapeutics, Inc. Common Shares (DFTX) trades on Nasdaq in USD, in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry.
Build with AI
Build an analysis of DFTX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a DFTX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.